迈微医疗完成亿元级人民币A+轮融资：专注心血管微无创治疗赛道

Core Viewpoint - The article highlights the successful A+ round financing of Pulsecare, emphasizing the recognition of its innovative technology in the cardiovascular intervention field and the significant clinical value of its NxPFA® system [3][4]. Financing and Investment - Pulsecare completed a significant financing round led by Yuanhe Origin, with participation from Zhengxin Valley Capital and existing shareholders [3]. - The funds raised will be used to accelerate the commercialization of the NxPFA® system and advance clinical research for its muRDN system [4][9]. Product Innovation - The NxPFA® system is the world's first and only approved nsPFA product, marking a new era in pulsed field ablation technology [5]. - The system offers significant advantages over previous technologies, including reduced nerve stimulation and improved safety and efficacy [5][6]. - The company is also developing a comprehensive cardiac electrophysiology solution that integrates 3D mapping, PFA, and ICE technologies [6]. Clinical Research and Development - The NxPFA® system has demonstrated a 100% immediate isolation rate of pulmonary veins and an 88.27% success rate one year post-operation in clinical studies [5]. - The muRDN system is in the registration phase, aiming to provide a breakthrough in hypertension treatment [7]. Market Potential - The article discusses the growing market potential for PFA and RDN technologies, with expectations of rapid revenue growth and market expansion [9]. - The company aims to leverage its innovative products to establish a strong presence in the global cardiovascular market [10]. Company Vision and Strategy - Pulsecare is committed to continuous innovation and integration of technology in the medical field, focusing on addressing clinical pain points and enhancing treatment value [8]. - The company plans to expand its global footprint and contribute to the prevention and control of cardiovascular diseases worldwide [8].